30.36
+4.26%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanghai INT Medical Instruments Co
Its shares trade on HKEX under the ticker 1501.HK. It has been listed since 8 November 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.24bn and net income of CN¥254.8m. At that date it held total assets of CN¥3.65bn and shareholders' equity of CN¥2.32bn.
Shanghai Kindly Medical Instruments Co., Ltd. engages in the research and development, manufacturing, and sales of interventional and implantable medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2019-11-08. The firm's cardiovascular intervention business is mainly engaged in the development, production and sales of cardiovascular interventional medical devices and related molds and accessories. The firm is also engaged in the development of other interventional and implantable medical devices, such as neurological interventional medical devices and endocardia implantable medical devices. The firm's main products include inflation device, Introducer set, guidewire and so on. The firm operates its business within the domestic market and to overseas markets including Europe and the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 8 Nov 2019
- Employees
- 1,532
- Website
- kdl-int.com ↗
Leadership
Pay as last reported
- Dr. Dongke LiangChairman, Executive Director, since 2006CN¥1.3m
- Mr. Cailiang WangGeneral Manager, Deputy General Manager, since 2010CN¥626,000
- Dr. Yuan SongGeneral Manager, Joint Company Secretary
- Mr. Qi ShiFinance Controller
- Ms. Shui Bing LeungJoint Company Secretary
- Ms. Hongqin ChenNon-Executive Director
- Mr. Shengshi FangNon-Executive Director
- Mr. Weixin ZhangNon-Executive Director
- Mr. Kerong DaiNon-Executive Independent DirectorCN¥120,000
- Mr. Hung Kwan HuiNon-Executive Independent DirectorCN¥120,000
- Mr. Xigao JianNon-Executive Independent DirectorCN¥120,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company engages in the research and development of interventional medical devices.
- It operates within both domestic and overseas markets including Europe and the United States.
- The firm employs 1,532 full-time employees as of the provided data.
Weaknesses
- The source description is explicitly treated as untrusted facts.
- Specific financial figures and revenue data are not provided in the text.
- Market share percentages and competitive positioning details are absent.
Opportunities
- The company develops neurological interventional medical devices for expansion.
- Endocardia implantable medical devices represent a growth area for the firm.
- Sales of related molds and accessories can diversify the product portfolio.
Threats
- Regulatory changes in overseas markets like Europe and the United States pose risks.
- Competition in the cardiovascular intervention business sector is implied by the industry.
- Reliance on untrusted source data limits the accuracy of this analysis.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.